[1]李新星.头孢呋辛钠+氨溴索治疗慢性支气管炎合并肺气肿的临床疗效及安全性[J].医学信息,2024,37(09):118-121.[doi:10.3969/j.issn.1006-1959.2024.09.022]
　LI Xin-xing.Clinical Efficacy and Safety of Cefuroxime Sodium+Ambroxol in the Treatment of Chronic Bronchitis Complicated with Emphysema[J].Journal of Medical Information,2024,37(09):118-121.[doi:10.3969/j.issn.1006-1959.2024.09.022]
点击复制

头孢呋辛钠+氨溴索治疗慢性支气管炎合并肺气肿的临床疗效及安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年09期
页码:
118-121
栏目:
论著
出版日期:
2024-05-01

文章信息/Info

Title:
Clinical Efficacy and Safety of Cefuroxime Sodium+Ambroxol in the Treatment of Chronic Bronchitis Complicated with Emphysema
文章编号:
1006-1959（2024）09-0118-04
作者:
李新星
（高安市瑞州医院呼吸内科，江西 高安 330800）
Author(s):
LI Xin-xing
(Department of Respiratory Medicine,Ruizhou Hospital,Gao’an 330800,Jiangxi,China)
关键词:
头孢呋辛钠; 氨溴索; 慢性支气管炎; 肺气肿
Keywords:
Cefuroxime sodium; Ambroxol; Chronic bronchitis; Emphysema
分类号:
R562；R563
DOI:
10.3969/j.issn.1006-1959.2024.09.022
文献标志码:
A
摘要:
目的 观察头孢呋辛钠+氨溴索治疗慢性支气管炎合并肺气肿的临床疗效及安全性。方法 选取2019年3月-2022年3月在我院诊治的80例慢性支气管炎合并肺气肿患者为研究对象，采用随机数字表法分为对照组和观察组，各组40例。对照组采用头孢呋辛钠治疗，观察组在对照组基础上联合氨溴索治疗，比较两组总有效率、临床症状改善时间、炎症因子水平、血气指标、不良反应发生情况。结果 观察组治疗总有效率（95.00%）高于对照组（82.50%）（P＜0.05）；观察组肺部X线片恢复、体温恢复时间以及住院时间均短于对照组（P＜0.05）；两组治疗后白细胞介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）均低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后动脉血氧分压（PaO2）高于治疗前，动脉血二氧化碳分压（PaCO2）低于治疗前，且观察组PaO2高于对照组，PaCO2低于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 头孢呋辛钠+氨溴索治疗慢性支气管炎合并肺气肿可提高临床疗效，改善血气指标，减轻临床症状，降低炎症因子水平，具有较高的临床应用价值。
Abstract:
Objective To observe the clinical efficacy and safety of cefuroxime sodium+ambroxol in the treatment of chronic bronchitis complicated with emphysema.Methods A total of 80 patients with chronic bronchitis complicated with emphysema who were diagnosed and treated in our hospital from March 2019 to March 2022 were selected as the research objects. They were divided into control group and observation group by random number table method, with 40 patients in each group. The control group was treated with cefuroxime sodium, and the observation group was treated with ambroxol on the basis of the control group. The total effective rate, clinical symptom improvement time, inflammatory factor level, blood gas index and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group (95.00%) was higher than that in the control group (82.50%) (P<0.05). The time of lung X-ray recovery, body temperature recovery and hospitalization in the observation group were shorter than those in the control group (P<0.05). After treatment, interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). After treatment, PaO2 in the two groups was higher than that before treatment, PaCO2 was lower than that before treatment, and PaO2 in the observation group was higher than that in the control group, PaCO2 was lower than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Cefuroxime sodium+ambroxol can improve the clinical efficacy of chronic bronchitis complicated with emphysema, improve the blood gas index, reduce clinical symptoms, reduce the level of inflammatory factors, and has high clinical application value.

参考文献/References:

[1]黄桔红,姚必瑜.布地奈德联合特布他林雾化治疗在慢性阻塞性肺病中的应用及对炎性因子的影响[J].中国生化药物杂志,2017,37(2):246-248.[2]王利玲,吴强鹏,程黎,等.肺纤维化合并肺气肿综合征的病理特征及影响因素分析[J].河北医药,2017,38(21):3299-3301.[3]傅显华.慢性支气管炎并发肺气肿的临床治疗分析[J].医学信息,2017,30(6):74-75.[4]马凤萍,谭光波.补肺汤对慢性阻塞性肺气肿大鼠外周血白细胞介素 -17、生长转化因子β1的影响[J].中医药临床杂志,2020,32(3):478-482.[5]丁明,袁成,李萍,等.稳定期慢性阻塞性肺气肿患者肺泡灌洗液中IL-8、IL-17水平的相关性研究[J].南京医科大学学报,2019,39(6):884-889.[6]袁晖.硫酸特布他林联合布地奈德雾化吸入治疗慢性阻塞性肺疾病的效果观察[J].山西医药杂志,2018,47(15):1790-1791.[7]白俊东,姚华强,张玉娜,等.头孢他啶联合氨茶碱治疗慢性阻塞性肺气肿的疗效及对血清IGF-1、α1-AT、PDGF-B 水平的影响[J].现代生物医学进展,2019,19(9):1762-1765.[8]吴苏佶,魏毅,石俊青,等.肺纤维化合并肺气肿综合征的临床特征与危险因素分析[J].中国呼吸与危重监护杂志,2021,20(1):4-11.[9]喻晴,沈其晓,韩丽莹,等.慢性阻塞性肺疾病患者肺气肿空间分布对肺功能及临床严重程度的影响[J].中国医学影像技术,2018,34(5):692-696.[10]唐晓霞,翁军,韩静.特布他林联合多索茶碱对慢性阻塞性肺疾病患者的疗效及患者呼吸动力学的影响[J].中国医院药学杂志,2020,40(15):62-65.[11]刘艳辉,李洪荣,范永会,等.班布特罗联合噻托溴铵粉治疗慢性阻塞性肺气肿的临床研究[J].现代药物与临床,2019,34(5):1374-1378. [12]陈蓉,冯钰.头孢他啶联合多索茶碱治疗对慢性阻塞性肺气肿患者外周血 TNF-α、PDGF-B 水平的影响[J].广西医科大学学报,2017,11(19):70-73.[13]孙冰清,赵洪文.多索茶碱联合噻托溴铵治疗慢性阻塞性肺疾病的疗效及安全性评价[J].国际呼吸杂志,2020,40(17):1287-1298.[14]Fernandez-Bussy S,Labarca G,Herth FJF.Bronchoscopic lung volume reduction in patients with severe emphysema[J].Semin Respir Crit Care Med,2018,39(6):685-692．[15]林亚发,程宏宁,张钦,等.头孢呋辛钠联合清开灵治疗老年肺气肿感染患者的临床效果研究[J].中华医院感染学杂志,2016,23(3):568-569．[16]欧阳惠利,赵亮.多索茶碱联合头孢他啶治疗慢性阻塞性肺疾病急性加重期临床观察[J].赣南医学院学报,2019,39(1):48-50.[17]武琰娇,张娜娜,柏少锋.异丙托溴铵联合乙酰半胱氨酸对慢性阻塞性肺疾病患者血浆与诱导痰巨噬细胞刺激蛋白表达及肺功能影响[J].临床军医杂志,2019,47(3):281-283.[18]张艳.痰热清联合头孢呋辛钠治疗151例老年肺气肿感染的临床疗效观察研究[J].山西医药杂志,2017,46(4):438-440.[19]尹智慧.噻托溴铵粉雾剂治疗慢性阻塞性肺气肿的临床分析[J].内蒙古医学杂志,2022,54(9):1103-1105.[20]靳小利.布地奈德联合异丙托溴铵对阻塞性肺气肿患者气血参数及肺功能的影响[J].实用医技杂志,2019,26(3):74-75.

相似文献/References:

[1]史贻芳.普米克令舒联合氨溴索治疗新生儿肺炎的临床疗效观察[J].医学信息,2018,31(04):132.[doi:10.3969/j.issn.1006-1959.2018.04.047]
　SHI Yi-fang.Clinical Effect of Pulmicort Combined with Ambroxol in the Treatment of Neonatal Pneumonia[J].Journal of Medical Information,2018,31(09):132.[doi:10.3969/j.issn.1006-1959.2018.04.047]
[2]刘成丽.氨溴索在哮喘性支气管炎治疗中的应用效果及安全性评价[J].医学信息,2018,31(05):138.[doi:10.3969/j.issn.1006-1959.2018.05.049]
　LIU Cheng-li.Efficacy and Safety Evaluation of Ambroxol in the Treatment of Asthmatic Bronchitis[J].Journal of Medical Information,2018,31(09):138.[doi:10.3969/j.issn.1006-1959.2018.05.049]
[3]罗玉霞.舒适护理在布地奈德联合氨溴索雾化吸入治疗 慢阻肺急性发作患者的效果分析[J].医学信息,2018,31(12):179.[doi:10.3969/j.issn.1006-1959.2018.12.058]
　LUO Yu-xia.Analysis of the Effect of Comfortable Nursing in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients with Aerosolized Inhalation of Budesonide and Ambroxol[J].Journal of Medical Information,2018,31(09):179.[doi:10.3969/j.issn.1006-1959.2018.12.058]
[4]陈孝辉.哌拉西林钠他唑巴坦钠联合氨溴索治疗慢性阻塞性肺疾病的临床效果[J].医学信息,2022,35(13):97.[doi:10.3969/j.issn.1006-1959.2022.13.021]
　CHEN Xiao-hui.Clinical Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Ambroxol in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(09):97.[doi:10.3969/j.issn.1006-1959.2022.13.021]
[5]曹文杰,李靖靖.痰热清注射液联合头孢呋辛钠治疗老年社区获得性肺炎的疗效[J].医学信息,2019,32(24):168.[doi:10.3969/j.issn.1006-1959.2019.24.062]
　CAO Wen-jie,LI Jing-jing.The Efficacy of Tanreqing Injection Combined with Cefuroxime Sodium in the Treatment of Community-acquired Pneumonia in the Elderly[J].Journal of Medical Information,2019,32(09):168.[doi:10.3969/j.issn.1006-1959.2019.24.062]
[6]刘斌先.布地奈德、沙丁胺醇雾化吸入联合氨溴索注射液治疗小儿支气管肺炎的效果及对WBC、CRP的影响[J].医学信息,2024,37(02):136.[doi:10.3969/j.issn.1006-1959.2024.02.027]
　LIU Bin-xian.Clinical Effect of Budesonide and Salbutamol Aerosol Inhalation Combined with Ambroxol Injection in the Treatment of Bronchial Pneumonia in Children and its Effect on WBC and CRP[J].Journal of Medical Information,2024,37(09):136.[doi:10.3969/j.issn.1006-1959.2024.02.027]
[7]陈菊花.左氧氟沙星与氨溴索联合治疗慢性阻塞性肺疾病合并肺部感染患者的疗效及安全性[J].医学信息,2024,37(24):85.[doi:10.3969/j.issn.1006-1959.2024.24.023]
　CHEN Juhua.Efficacy and Safety of Levofloxacin Combined with Ambroxol in the Treatment of Patients with Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection[J].Journal of Medical Information,2024,37(09):85.[doi:10.3969/j.issn.1006-1959.2024.24.023]

更新日期/Last Update: 1900-01-01